Cilastatin

Research use only, not for human use.

A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor.

A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, imipenem, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4.(In Vitro):Cilastatin (200 μg/mL; 24 hours; RPTECs) treatment protects against Vancomycin-induced proximal tubule apoptosis and increases cell viability, without compromising the antimicrobial effect of Vancomycin.(In Vivo):In a mouse model (female mice, strain CD-1, 20 g) of systemic infection, Imipenem plus Cilastatin can protect mice from S. aureus, E. coli, and P. aeruginosa infection.

Cilastatin (200 μg/mL; 24 hours; RPTECs) treatment protects against Vancomycin-induced proximal tubule apoptosis and increases cell viability, without compromising the antimicrobial effect of Vancomycin. Apoptosis Analysis Cell Line:Renal proximal tubular epithelial cells (RPTECs) Concentration:200 μg/mL Incubation Time:24 hours Result:Significantly ameliorated Vancomycin-induced nuclear apoptosis.

In a mouse model (female mice, strain CD-1, 20 g) of systemic infection, Imipenem plus Cilastatin can protect mice from S. aureus, E. coli, and P. aeruginosa infection.

——

Proteasome/Ubiquitin

Proteasome

Dipeptidase 1

——

——

82009-34-5

358.45

C16H26N2O5S

>98% (HPLC)

DMSO: 10 mM

CC1(C[C@H]1C(=O)N/C(=C\CCCCSC[C@H](C(=O)O)N)/C(=O)O)C

——

(-20℃)

With Ice Pack

≥ 2 years